TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company’s Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin compounds block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.

TetraLogic’s Smac Mimetics have demonstrated striking preclinical activity in a wide range of cancers when administered as single agents or in combination with other cancer therapies. The lead development candidate, TL132711, is expected to enter human clinical trials during 2009.

TetraLogic’s Necrostatins inhibit cell death triggered by a variety of cell death stimuli. Activity has been demonstrated in several in-vivo models of cardiovascular, neurological and ophthalmic diseases and injuries. TetraLogic expects to commence human clinical studies with its lead Necrostatin drug candidate during 2010.